IVF INVO Fertility, Inc.

MIXED Impact: 5/10 8-K
Horizon weeks Filed Jun 2, 2026 Processed 12d 19h ago SEC 0001493152-26-026777
8-K Item 2.02: Earnings release
Latest settled — T+1d ⚠ clustered
IVF ▲ +11.84% at T+1d
NEUTRAL call ✓ call won +11.84% · α vs SPY +12.54% · entry $1.52 → $1.70
Next anchor: T+5d due 6d ago
Last close $1.48 (close Jun 12) · -2.63% from $1.52 entry
Entry anchored
Jun 2, 05:35 AM ET
via Databento tick
T+1d
+11.84%
call +11.84% · α +12.54%
$1.70
settled 12d ago
T+5d
call — · α —
due 6d ago
T+20d
call — · α —
in 16d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

INVO Fertility reported FY2025 revenue of $6.84M (+5% YoY) and a net loss from continuing operations of $(5.3)M, improved from $(7.7)M in FY2024. The company highlighted a strengthened balance sheet with $11.5M in recent financing, the acquisition of Family Beginnings, and the elimination of Series C-2 Preferred and warrant liabilities. However, Adjusted EBITDA worsened to $(3.2)M from $(2.2)M, and the net loss attributable to common shareholders was $(25.1)M due to discontinued operations and warrant deemed dividends.

Actionable Insight

The filing shows a mixed picture: improving revenue and narrowing operating loss from continuing operations, but a worsening Adjusted EBITDA and a massive net loss from discontinued operations. The balance sheet strengthening and acquisition provide a positive narrative, but the company remains deeply unprofitable with a $2M market cap. Monitor for the next quarterly filing to see if organic growth initiatives and the Family Beginnings acquisition translate into improving cash flows.

Key Facts

  • FY2025 revenue of $6,841,250, up 5% from $6,532,000 in FY2024.
  • Net loss from continuing operations improved to $(5.3)M from $(7.7)M.
  • Adjusted EBITDA worsened to $(3.2)M from $(2.2)M.
  • Closed acquisition of Family Beginnings in February 2026, adding ~$1.2M in trailing revenue.
  • Raised $11.5M in gross proceeds from December 2025 and January 2026 financings.
  • All Series C-2 Preferred converted or retired; warrant liabilities eliminated.
  • Net loss attributable to common shareholders was $(25.1)M, including $(16.5)M from discontinued operations and $(1.8)M in warrant deemed dividends.
  • Weighted average basic shares outstanding: 117,083 in FY2025 vs 2,514 in FY2024.

Financial Impact

Revenue growth of 5% to $6.84M; net loss from continuing ops improved by ~31% to $(5.3)M; Adjusted EBITDA declined by 41% to $(3.2)M.

revenuenet lossadjusted EBITDAcash flow

Risk Factors

  • Continued operating losses and negative Adjusted EBITDA.
  • Massive net loss from discontinued operations ($16.5M) and warrant deemed dividends ($1.8M).
  • Extremely low market cap ($2M) and thin trading liquidity.
  • Dependence on future acquisitions and financing for growth.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (5 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-026777
Document: form8-k.htm0001493152-26-026777
Document: 0001493152-26-026777-index-headers.html0001493152-26-026777
Document: 0001493152-26-026777-index.html0001493152-26-026777
Document: 0001493152-26-026777.txt0001493152-26-026777
8-K Data (Synthetic)0001493152-26-026777
6 reports for IVF
Performance horizon
33% Hit rate 1 of 3 directional calls best @ T+1▲ +2.35%Jun 2, 2026
Filters
Rows
Reports for IVF — sortable, filterable
Type Now
Jun 2, 2026
12d ago
Press Release
BEARISH ★ 6/10
$1.70 $1.66▲ +2.35%▲ +2.75%$1.48 (+12.94%)
Jun 2, 2026
12d ago
8-K
MIXED ★ 5/10
$1.52 $1.70▲ +11.84%▲ +12.54%$1.48 (−2.63%)
Jun 2, 2026
12d ago
8-K
BEARISH ★ 8/10
$1.52 $1.70▼ −11.84%▼ −12.54%$1.48 (+2.63%)
Jun 2, 2026
12d ago
Press Release
MIXED ★ 5/10
$1.52 $1.70▲ +11.84%▲ +12.54%$1.48 (−2.63%)
Mar 3, 2026
14w ago
Press Release
NEUTRAL ★ 4/10
$4.33 $4.44▲ +2.54%▲ +1.78%$1.48 (−65.78%)
Feb 24, 2026
15w ago
8-K
BULLISH ★ 8/10
$5.00 $4.97▼ −0.50%▼ −1.33%$1.48 (−70.37%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 5h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access